{"id":"W3032096744","doi":"10.1200/jco.2020.38.15_suppl.9001","title":"KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Placebo; Carboplatin; Internal medicine; Population; Etoposide; Interim analysis; Pembrolizumab; Clinical endpoint; Oncology; Clinical trial; Cisplatin; Chemotherapy; Cancer; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001152028,0.000972109,0.001398301,0.0007879016,0.0003281322,0.0006444532,0.0009993488,0.001212549,0.01597359],"category_scores_gemma":[0.0008118126,0.0004410115,0.0007029819,0.0004468754,0.0006134771,0.0009444404,0.000472564,0.001946434,0.001675771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005615553,"about_ca_system_score_gemma":0.0009446456,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002855125,"about_ca_topic_score_gemma":0.0009519046,"domain_scores_codex":[0.9996393,0.0001466082,0.0000412595,0.00007512692,0.00003457837,0.00006317235],"domain_scores_gemma":[0.9996822,0.00005070908,0.00008304412,0.00002848944,0.0000117723,0.0001438256],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8487657,0.01589666,0.000886243,0.001930834,0.0007528497,0.0001116667,0.00007545586,0.000878353,0.02714879,0.0006623417,0.004609983,0.09828097],"study_design_scores_gemma":[0.809316,0.1718075,0.003912592,0.0001242487,0.0007320389,0.0002361427,0.00002796296,0.000742186,0.006640204,0.0004831819,0.005951599,0.0000262807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9553938,0.008682531,0.003060129,0.001104984,0.0007792325,0.01313473,0.004309337,0.0007658022,0.01276941],"genre_scores_gemma":[0.9796322,0.00277777,0.003075496,0.0008145469,0.000237448,0.005965095,0.001780784,0.00004764802,0.005669113],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01597359,"threshold_uncertainty_score":0.05343699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2029837320610601,"score_gpt":0.5117943962480638,"score_spread":0.3088106641870036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}